Market Overview

UPDATE: Wedbush Initiates PTC Therapeutics at Outperform on Ataluren Potential

Share:
Related PTCT
Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst
Barclays Expands Coverage To 7 New Biotech Stocks

In a report published Wednesday, Wedbush analyst Christopher N. Marai initiated coverage on PTC Therapeutics (NASDAQ: PTCT) with an Outperform rating and $55.00 price target.

In the report, Wedbush noted, “PTC is developing ataluren, a molecularly targeted Phase III drug candidate for the treatment of genetically-defined rare and ultra-rare diseases caused by nonsense mutations. PTC is currently enrolling patients with Duchenne muscular dystrophy caused by nonsense mutations (nmDMD) in a large randomized Phase III clinical trial expected to readout mid:2015. Ataluren may also receive conditional approval in the EU in YE:13 based on the results of a Phase IIb trial in nmDMD. Ataluren may be broadly applicable, beyond initial indications, to 12% of all hereditary diseases and nonsense mutation driven cancers. There are ~2,400 genetically-defined rare diseases caused by nonsense mutations. We estimate that ataluren could be worth >$1.5 billion in peak sales in nmDMD and nmCF alone.”

PTC Therapeutics closed on Tuesday at $16.57.

Latest Ratings for PTCT

DateFirmActionFromTo
Mar 2015BarclaysInitiates Coverage onOverweight
Mar 2015JP MorganDowngradesOverweightNeutral
Nov 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Christopher N. Marai WedbushAnalyst Color Initiation Analyst Ratings

 

Related Articles (PTCT)

Around the Web, We're Loving...